Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 92 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Feraheme Clear all
Enrolling by invitation Phase 4 Interventional

Nanozymes in Endodontics

NCT07518901
View directory record Official record
Conditions
Apical Periodontitis, Endodontic Disease, Root Canal Infection
Interventions
Nanozyme treatment, Control (Standard treatment)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 7:37 AM EDT
Completed Phase 1 Interventional Results available

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

NCT01770353
View directory record Official record
Conditions
Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
Interventions
Ferumoxytol, MM-398
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 17, 2026, 7:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women

NCT00360425
View directory record Official record
Conditions
Anemia
Interventions
ferumoxytol, moxifloxacin, placebo
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 17, 2026, 7:37 AM EDT
Completed Phase 2 Interventional Results available

Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)

NCT00707876
View directory record Official record
Conditions
Peripheral Arterial Disease (PAD)
Interventions
ferumoxytol
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 17, 2026, 7:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

NCT01542879
View directory record Official record
Conditions
Cancer
Interventions
WB-DW-MR scan, 18-F-FDG PET scan, Ferumoxytol, 18-F-FDG PET/MR scan
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
6 Years to 40 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 17, 2026, 7:37 AM EDT
Completed No phase listed Observational

Quantitative Non-Invasive Brain Imaging Using QUTE-CE MRI

NCT03266848
View directory record Official record
Conditions
Cerebrovascular Disorders
Interventions
Quantitative Magnetic Resonance Imaging
Diagnostic Test
Lead sponsor
Theranano LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 17, 2026, 7:37 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects

NCT03893045
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
ferumoxytol, Iron sucrose
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
6
States / cities
Little Rock, Arkansas • Gainesville, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 17, 2026, 7:37 AM EDT
Recruiting Phase 4 Interventional

Early Antenatal Support for Iron Deficiency Anemia

NCT04278651
View directory record Official record
Conditions
Pregnancy Related, Anemia, Iron Deficiency, Anemia of Pregnancy
Interventions
Ferumoxytol, Ferrous Sulfate
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 17, 2026, 7:37 AM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia

NCT01114139
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol, Placebo
Drug · Other
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
812 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
137
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 105 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 17, 2026, 7:37 AM EDT
Not listed No phase listed Observational

Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers

NCT04682847
View directory record Official record
Conditions
Liver Neoplasms, Hepatic Cirrhosis, Hepatic Carcinoma, Liver Cancer, Liver Metastases, Liver Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatic Atrophy
Interventions
Ferumoxytol injection
Drug
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 17, 2026, 7:37 AM EDT
Active, not recruiting Phase 1 Interventional Results available

A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma

NCT04900792
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
Ferumoxytol injection, Pharmacological ascorbate, External beam radiation therapy, Temozolomide
Drug · Radiation
Lead sponsor
Bryan Allen
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 17, 2026, 7:37 AM EDT
Recruiting Phase 2 Interventional

Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

NCT03270059
View directory record Official record
Conditions
Central Nervous System Neoplasm, Cranial Nerve Disorder, Metastatic Malignant Neoplasm in the Brain
Interventions
Ferumoxytol, Gadolinium, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
10 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 17, 2026, 7:37 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Active Preoperative Anemia Management in Patients Undergoing Cardiac Surgery

NCT02189889
View directory record Official record
Conditions
Anemia, Cardiovascular Disease
Interventions
EPO, Feraheme
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 17, 2026, 7:37 AM EDT
Terminated Phase 4 Interventional Results available

Study to Assess Feasibility and Safety of Iron Repletion With Feraheme in Iron Deficient Patients With Durable Ventricular Assist Device Support

NCT04080908
View directory record Official record
Conditions
Anemia
Interventions
Ferumoxytol injection
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
19 Years to 110 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 17, 2026, 7:37 AM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases

NCT03325166
View directory record Official record
Conditions
Lung Carcinoma Metastatic in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Ferumoxytol, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pembrolizumab
Drug · Other · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 17, 2026, 7:37 AM EDT
Completed Phase 3 Interventional Results available

A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia

NCT01114217
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
634 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
103
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 76 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 17, 2026, 7:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging

NCT01815333
View directory record Official record
Conditions
Cancer of Lymph Node
Interventions
Feraheme, Magnetic Resonance Imaging (MRI)
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 17, 2026, 7:37 AM EDT
Recruiting Phase 2 Interventional

Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants

NCT05340465
View directory record Official record
Conditions
Prematurity, Iron-deficiency, Iron Deficiency Anemia, Iron Malabsorption
Interventions
Darbepoetin Alfa, Low Molecular Weight Iron Dextran, Ferumoxytol injection, Oral iron supplements
Drug
Lead sponsor
University of Washington
Other
Eligibility
Up to 3 Days
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 17, 2026, 7:37 AM EDT
Completed Phase 4 Interventional Results available

Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)

NCT00920023
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Superparamagnetic Iron Oxide Magnetic Resonance Imaging
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 17, 2026, 7:37 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Ferumoxytol-enhanced Imaging and Mapping in neuroAIDS

NCT02678767
View directory record Official record
Conditions
AIDS Dementia Complex
Interventions
Ferumoxytol
Drug
Lead sponsor
Beau Nakamoto
Other
Eligibility
40 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Oct 27, 2017 · Synced Oct 17, 2026, 7:37 AM EDT
Completed No phase listed Observational

Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency Anemia

NCT01984554
View directory record Official record
Conditions
Iron Deficiency Anemia (IDA)
Interventions
Not listed
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 17, 2026, 7:37 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study: Randomized, Placebo-controlled Comparator Trial of IV vs Oral Iron Treatment of RLS With IDA. (IVOR-IDA)

NCT02499354
View directory record Official record
Conditions
Restless Legs Syndrome, Iron Deficiency Anemia
Interventions
Ferumoxytol intravenous, Ferrous sulfate
Drug
Lead sponsor
Auerbach Hematology Oncology Associates P C
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 17, 2026, 7:37 AM EDT
Recruiting Phase 3 Interventional

Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients

NCT07461948
View directory record Official record
Conditions
Glioblastoma
Interventions
Biospecimen Collection, Chemical Exchange Saturation Transfer Magnetic Resonance Imaging, Diffusion-Relaxation Correlation Spectrum Imaging, Electronic Health Record Review, Ferumoxytol, Magnetic Resonance Imaging
Procedure · Other · Drug + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 17, 2026, 7:37 AM EDT
Terminated Phase 2 Interventional Results available

Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors

NCT00659126
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain, Primary Brain Neoplasm
Interventions
3 Tesla Magnetic Resonance Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol, Gadolinium, High Field Strength Magnetic Resonance Imaging, Susceptibility Weighted Imaging
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 17, 2026, 7:37 AM EDT